Article
Biochemistry & Molecular Biology
Jannik Rousel, Mahdi Saghari, Lisa Pagan, Andreea Nadaban, Tom Gambrah, Bart Theelen, Marieke L. de Kam, Jorine Haakman, Hein E. C. van der Wall, Gary L. Feiss, Tessa Niemeyer-van der Kolk, Jacobus Burggraaf, Joke A. Bouwstra, Robert Rissmann, Martijn B. A. van Doorn
Summary: This study evaluated the effectiveness of omiganan in the treatment of facial seborrheic dermatitis. The results showed that omiganan did not significantly improve clinical symptoms or other biomarkers. In contrast, ketoconazole significantly reduced disease severity and had positive effects on Malassezia abundances, microbial diversity, and skin barrier function. The importance of evaluating omiganan in the treatment of facial seborrheic dermatitis is limited.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Health Care Sciences & Services
Simona Roxana Georgescu, Cristina Iulia Mitran, Madalina Irina Mitran, Andreea Amuzescu, Clara Matei, Mircea Tampa
Summary: This study evaluated the efficacy of sertaconazole 2% cream in patients with seborrheic dermatitis. The results showed that sertaconazole treatment was associated with a higher percentage of patients with mild symptoms and a lower percentage of patients with moderate or severe symptoms compared to other treatments. Sertaconazole may be an efficient alternative therapy for seborrheic dermatitis.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Dermatology
Philippe Massiot, Cecile Clavaud, Marie Thomas, Alban Ott, Audrey Gueniche, Segolene Panhard, Benoit Muller, Celine Michelin, Delphine Kerob, Anne Bouloc, Pascal Reygagne
Summary: The study investigated the changes in scalp microbiota diversity and counts in subjects with scalp seborrheic dermatitis during a two-phase treatment period. Both ketoconazole and selenium disulfide showed improvement in clinical symptoms of SD.
JOURNAL OF COSMETIC DERMATOLOGY
(2022)
Review
Dermatology
Xiaomei Chen, Hongmei Xiang, Ming Yang
Summary: This study summarized the evidence regarding the effectiveness and safety of using topical cetirizine for treating androgenetic alopecia, suggesting that 1% topical cetirizine may be more effective than a placebo. However, compared to minoxidil, it was found to be less effective in improving total and vellus hair density, but it may have a longer-lasting effect.
JOURNAL OF COSMETIC DERMATOLOGY
(2022)
Review
Dermatology
Jacob Griggs, Brandon Burroway, Antonella Tosti
Summary: Androgenetic alopecia is not uncommon in the pediatric population, but its exact incidence and prevalence remain unclear. It is usually diagnosed clinically by physical examination and trichoscopy, and topical minoxidil has shown success in treatment despite lacking approval. Other treatment modalities in children are under-studied.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Chemistry, Physical
Ruxuan Wang, Tengjiang Zhong, Qiong Bian, Sai Zhang, Xiaolu Ma, Liming Li, Yihua Xu, Yueting Gu, Anran Yuan, Weitong Hu, Chong Qin, Jianqing Gao
Summary: A novel proteolysis targeting chimera degrader of androgen receptor (AR-PROTAC) was synthesized and integrated with dissolving microneedles (PROTAC-MNs) for the treatment of androgenetic alopecia (AGA). The PROTAC-MNs showed mechanical capabilities for precise delivery of AR-PROTAC into hair follicles, resulting in accelerated hair regeneration compared to minoxidil. Furthermore, the PROTAC-MNs regulated the signaling cascade related to hair growth and activated hair follicle stem cells, providing great therapeutic potential for AGA treatment.
Article
Mycology
Mervat Hamdino, Amany Ahmed Saudy, Laila Hussein El-Shahed, Mohamed Taha
Summary: This study identified Malassezia species in lesions of patients with pityriasis versicolor, atopic dermatitis, and seborrheic dermatitis, as well as corresponding sites in healthy subjects, using culture methods. The study found that M. furfur was a common isolated species in all groups, while M. sympodialis was the prevalent species in atopic dermatitis lesions.
JOURNAL DE MYCOLOGIE MEDICALE
(2022)
Review
Infectious Diseases
Iniobong Chukwuebuka Ikenna Ugochukwu, Wafa Rhimi, Wissal Chebil, Antonio Rizzo, Maria Tempesta, Gustavo Giusiano, Raul Fernando Mejia Tabora, Domenico Otranto, Claudia Cafarchia
Summary: Malassezia yeasts are part of the skin mycobiota and can become opportunistic pathogens, causing various skin disorders. The interaction between the host skin and Malassezia spp. leads to the production of virulence factors or metabolites that contribute to the development of different clinical presentations of skin disorders.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
(2023)
Article
Dermatology
Zari Shadi
Summary: This study assessed the levels of compliance to topical minoxidil (TM) among male and female patients with androgenetic alopecia (AGA) and analyzed the factors associated with minoxidil discontinuation. The clinical use of TM in AGA is limited by a substantially low compliance even in absence of adverse effects. We emphasize the importance of educating patients regarding the treatment's side effects and the need to use minoxidil for a minimum of 12 months to assess treatment efficacy.
DERMATOLOGY AND THERAPY
(2023)
Article
Cell Biology
Yeong Chan Ryu, Jiyeon Park, You-Rin Kim, Sehee Choi, Geon-Uk Kim, Eunhwan Kim, Yumi Hwang, Heejene Kim, Gyoonhee Han, Soung-Hoon Lee, Kang-Yell Choi
Summary: The number of people suffering from hair loss is increasing, affecting not only older men but also women and young people. This study reveals that CXXC5 acts as a mediator for hair loss induced by prostaglandin D-2 (PGD(2)) through suppression of the Wnt/beta-catenin signaling pathway. CXXC5 inhibition or activation of the Wnt/beta-catenin pathway can restore hair loss caused by PGD(2) or overcome suppression of neogenic hair growth.
Review
Dermatology
Aditya K. Gupta, Mesbah Talukder, Mary A. Bamimore
Summary: This article reviews the potential of natural products in treating male androgenetic alopecia (AGA). The selected clinical studies suggest that saw palmetto, caffeine, melatonin, marine extracts, rosemary oil, procyanidin, pumpkin seed oil, and cannabidiol oil might be considered in male AGA treatment.
DERMATOLOGIC THERAPY
(2022)
Article
Dermatology
Hamza Abdel-Raouf, Usama F. Aly, Walid Medhat, Shimaa S. Ahmed, Rasha T. A. Abdel-Aziz
Summary: Topical minoxidil 5% and topical spironolactone 1% were both effective in treating AGA, with the combination of the two agents showing the best results. The study included 60 patients diagnosed with AGA, with significant improvements in both clinical and histopathological examinations observed after the treatment period.
DERMATOLOGIC THERAPY
(2021)
Article
Dermatology
B. M. Piraccini, U. Blume-Peytavi, F. Scarci, J. M. Jansat, M. Falques, R. Otero, M. L. Tamarit, J. Galvan, V Tebbs, E. Massana
Summary: The study showed that topical finasteride performed better than placebo in improving hair count and was well tolerated. Compared to oral finasteride, topical finasteride had similar effects on hair growth but showed significantly lower systemic exposure and less impact on serum DHT concentrations.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Chaohui Zhang, Yixin Yu, Shugao Shi, Manman Liang, Dongqin Yang, Ning Sui, William W. Yu, Lina Wang, Zhiling Zhu
Summary: This study discovered a highly efficient SOD mimic for the treatment of androgenetic alopecia (AGA). By using machine learning techniques, a MnPS3 with a low IC50 value was identified, which can effectively remove reactive oxygen species. A MnPS3 microneedle patch was constructed, which exhibits better hair regeneration ability.
Article
Chemistry, Medicinal
Yuqing Shen, Yuqi Zhu, Li Zhang, Jiayi Sun, Bo Xie, Hongyan Zhang, Xiuzu Song
Summary: The mechanism of minoxidil in treating androgenetic alopecia (AGA) was investigated through network pharmacology. The results identified that minoxidil targets not only androgenic receptors (AR) but also two new targets, steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1) and aromatase (CYP19A1). Further experiments revealed that minoxidil inhibits AR and CYP17A1 expression, increases CYP19A1 activity, reduces dihydrotestosterone formation and binding, and enhances estradiol production, thus treating AGA.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2023)
Review
Dermatology
Franchesca D. Choi, Christina N. Kraus, Ashley N. Elsensohn, Sama K. Carley, Larisa M. Lehmer, Rebecca T. Nguyen, Kenneth G. Linden, Jessica Shiu
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2020)
Review
Dermatology
Franchesca Choi, Larisa Lehmer, Chloe Ekelem, Natasha A. Mesinkovska
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2020)
Review
Dermatology
Ajay N. Sharma, Delila P. Foulad, Linda Doan, Patrick K. Lee, Natasha Atanaskova Mesinkovska
Summary: This study compares the efficacy of Mohs micrographic surgery (MMS) with traditional surgical and nonsurgical therapies for lentigo maligna (LM) and lentigo maligna melanoma (LMM). Results indicate that MMS has a lower recurrence rate compared to other treatment options, making it a successful choice for these conditions. Further clinical trials are needed to better understand the role of MMS in the treatment algorithm for LM and LMM.
JOURNAL OF DERMATOLOGICAL TREATMENT
(2021)
Review
Dermatology
Christine T. Pham, Alfred Lee, Calvin T. Sung, Franchesca Choi, Margit Juhasz, Natasha A. Mesinkovska
DERMATOLOGIC SURGERY
(2020)
Article
Dermatology
Kw Wyrwich, H. Kitchen, S. Knight, N. V. J. Aldhouse, J. Macey, F. P. Nunes, Y. Dutronc, N. Mesinkovska, J. M. Ko, B. A. King
BRITISH JOURNAL OF DERMATOLOGY
(2020)
Article
Dermatology
Chloe Ekelem, Nate Feil, Ella Csuka, Margit Juhasz, Jessica Lin, Franchesca Choi, Arya Asghari, Dorsa Heydarlou, Natasha A. Mesinkovska
Summary: This pilot study aims to provide an atlas of OCT findings of healthy and alopecia subjects, explore diagnostic quantitative endpoints of alopecia, and compare epidermal thickness and follicular density between scalp regions. Qualitative differences of OCT images are identified in sample images from healthy scalp and each subtype of alopecia studied. OCT holds promise as a non-invasive technique to further characterize and objectively measure alopecia, but larger sample sizes and longitudinal data are needed for improved reliability.
LASERS IN SURGERY AND MEDICINE
(2021)
Article
Dermatology
Kathleen W. Wyrwich, Helen Kitchen, Sarah Knight, Natalie V. J. Aldhouse, Jake Macey, Fabio P. Nunes, Yves Dutronc, Natasha Mesinkovska, Justin M. Ko, Brett A. King
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2020)
Review
Dermatology
Calvin T. Sung, Tiffany Chao, Alfred Lee, Delila Pouldar Foulad, Franchesca Choi, Margit Juhasz, Allison Dobry, Natasha Atanaskova Mesinkovska
JOURNAL OF DRUGS IN DERMATOLOGY
(2020)
Article
Dermatology
Gregor Urban, Nate Feil, Ella Csuka, Kiana Hashemi, Chloe Ekelem, Franchesca Choi, Natasha A. Mesinkovska, Pierre Baldi
Summary: This study proposes the use of OCT and deep learning to count hair follicles, providing a more accurate and efficient monitoring of alopecia treatment success. The deep learning system predicts follicle count with an error rate of 11.8% and hair count with an error rate of 18.7% on average.
LASERS IN SURGERY AND MEDICINE
(2021)
Letter
Dermatology
C. Nguyen, K. Yale, F. Casale, A. Ghigi, K. Zheng, J. I. Silverberg, N. A. Mesinkovska
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
Jake Macey, Helen Kitchen, Natalie V. J. Aldhouse, Emily Edson-Heredia, Russel Burge, Apurva Prakash, Brett A. King, Natasha Mesinkovska
Summary: This study aimed to explore the content validity of patient-reported outcome measures in adolescents with alopecia areata. Hair loss, eyebrow loss, and eyelash loss were identified as the most bothersome symptoms. The results confirmed that these measurement tools are impactful for adolescents.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Review
Dermatology
D. M. Hutchison, A. Duffens, K. Yale, A. Park, K. Cardenas, N. A. Mesinkovska
Summary: This study systematically reviewed potential causes of eyelash trichomegaly, identifying medications, surgical procedures, and medical conditions that can lead to abnormal eyelash growth. Different pharmacological agents like prostaglandin analogues were found to increase eyelash growth, along with congenital disorders that can cause elongated eyelashes.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2022)
Article
Health Care Sciences & Services
Kathleen W. Wyrwich, Helen Kitchen, Sarah Knight, Natalie V. J. Aldhouse, Jake Macey, Natasha Mesinkovska, Justin M. Ko, Brett A. King
Summary: Traditionally, appropriate anchors are used to investigate the amount of change on a clinician-reported outcome assessment that is meaningful to individual patients. However, novel qualitative methods involving input from disease state experts together with patients may better inform the individual improvement threshold for demonstrating the clinical benefit of new treatments. This study aimed to establish a clinically meaningful threshold for treatment success for the clinician-reported Severity of Alopecia Tool (SALT) score for patients with alopecia areata (AA).
QUALITY OF LIFE RESEARCH
(2023)
Article
Immunology
Colin M. Kincaid, Justin D. Arnold, Natasha A. Mesinkovska
Summary: Alopecia areata is an immune-mediated hair loss disorder that affects any hair-bearing site on the body. Treatment options have been limited in effectiveness, especially for severe forms of the disease. However, Janus kinase inhibitors, specifically baricitinib, have shown significant hair regrowth in clinical trials and have become the first approved systemic therapy for severe alopecia areata.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2023)
Article
Dermatology
Natasha Mesinkovska, Brittany Craiglow, Susan G. Ball, Paula Morrow, Sarah G. Smith, Evangeline Pierce, Jerry Shapiro
Summary: This cross-sectional study found that the psychological and social consequences and emotional burden of alopecia areata (AA) are often underestimated. More severe hair loss is associated with longer duration of experiencing AA symptoms and greater negative psychological impact and poorer quality of life (QoL).
DERMATOLOGY AND THERAPY
(2023)
